An interventional study of HT Helper app use plus patient navigation support and Patient Navigation support alone in Treatment Adherence, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Treatment Adherence and Compliance with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Treatment Adherence and Compliance · United States.
Among the 75 studies in Treatment Adherence and Compliance with a site in United States, this one is the 19th largest by planned enrollment of the 70 interventional ones that give a count, is one of 2 that started in 2025, is one of 58 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 72nd registered.
353 studies on the registry are indexed under Treatment Adherence and Compliance; 108 are open to participants now.
Browse Treatment Adherence and Compliance studies →12 of the 75 studies in Treatment Adherence and Compliance with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 18–65
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18+
Lifespan · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 59 Treatment Adherence and Compliance studies recruiting now, 46 (78%) set no upper age limit and 12 (20%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 4 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 159 is above the median of 83 across 273 interventional studies indexed under Treatment Adherence and Compliance.
Median enrollment 66 across the 70 interventional studies, 384 across the 5 observational. Of the 57 that completed or were terminated, 23 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 75 have an industry lead sponsor. The 10 most frequent:
The University of Texas Health Science Center at San Antonio is the lead sponsor of 445 studies on the registry; 89 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 35 (54%) have results posted.
The University of Texas Health Science Center at San Antonio has 2 studies filed under Treatment Adherence and Compliance — fewer than ten, so there is no comparison to draw.
7 of the studies in Treatment Adherence and Compliance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05489068University of New MexicoMotivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment | 2026-12-01 |
| NCT07542769Northwestern UniversityChoice and Autonomy in Learning Mindfulness for Pediatric Residents | 2026-12-31 |
| NCT07881783Novartis PharmaceuticalsA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy | 2027-03-31 |
| NCT05973838University of Maryland, College ParkPeer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention | 2027-07-01 |
| NCT06909552University of Colorado, DenverUse of an Educational Video to Improve Adherence to Treatment in Voiding Dysfunction | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 75 studies in Treatment Adherence and Compliance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Hormonal therapy (HT) is highly effective for nearly all breast cancer patients with hormone receptor-positive tumors, which are about 80% of all breast cancer diagnoses. Long-term use of HT reduces cancer recurrence rates and cuts the risk of mortality nearly in half during the second decade after diagnosis. Despite proven benefits, 33% of women who are prescribed HT do not take it as prescribed (\<80% take their daily dosage). Latina patients are disproportionately affected by non-medical drivers of health (NMDoH) that keep them from adhering to HT and are at higher risk of breast cancer recurrence and mortality.
Objective: The goal of this 4-year randomized controlled study is to assess the effectiveness of the bilingual, culturally tailored, interactive HT Helper App, in combination with patient navigation (PN), on improving adherence to HT among Latina breast cancer patients experiencing any NMDoH barriers, such as income, health insurance, education, health literacy, and language, that impact their medication adherence. This theory-based intervention will increase patient education, enhance self-efficacy, facilitate communication with the medical team and coordination of resources to address NMDoH barriers, and help patients develop self-care skills for optimal adherence to HT, ensuring patients the most equitable treatment outcomes possible, including improvement in quality of life, survival, and life expectancy.
Specific Aims/Hypothesis: 1) Conduct a 3-group randomized study to assess the effectiveness of the HT Helper App + PN vs. PN alone vs. usual care, on HT adherence; and 2) Assess the effect of each study condition on patient self-efficacy to identify side effects, use self-care to manage side effects, and communicate with the medical team. We hypothesize that the HT Helper App + PN and the PN alone groups will have greater rates of HT adherence and higher patient self-efficacy than the usual care group; with the HT Helper App + PN achieving better results than both PN alone and the usual care groups.
Study Design. The proposed study involves a parallel 3-group randomized controlled trial with 5-time assessments (baseline, 3, 6, 12, and 18 months) and will enroll 159 breast cancer patients who are prescribed HT and are attending the breast clinic at the Mays Cancer Center at UT Health San Antonio. Intervention components are based on Social Cognitive Theory and elements of Motivational Interviewing.
Cancer Relevance. This innovative multi-level intervention will improve adherence to HT by addressing NMDoH and promote equitable breast cancer outcomes, including reduced recurrence and improved quality of life, overall survival, and life expectancy among underserved Latina patients. The anticipated outcome is a scalable, evidence-based, and easily disseminated intervention with potentially broad use to patients using oral anticancer medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
English- or Spanish-speaking Latina patients aged 18 and older who:
a) are diagnosed with hormone receptor-positive breast cancer and prescribed HT; b) within 1 to 24 months of starting HT; c) are experiencing any NMDoH by the Avanzando Center NMDoH Screener; d) are able to read; e) own a smartphone and are able to send and receive text messages and access the Internet; and f) are able to provide to participate in the study.
Exclusion Criteria:
Not meeting the criteria above, or patients who:
a) are not Latina and are younger than 18 years; b) are not receiving HT treatment; c) with more than 24 months of starting treatment; d) do not experience any NMDoH by the Avanzando Center NMDoH Screener; e) are unable to read; f) do not own a smartphone and are unable to send and receive text messages and access the Internet; g) are unable to respond to text messages and questions or unable to download the study app; h) are unable to provide due to a mental, emotional, or physical handicap that keeps them from understanding the consent information; i) are unable to see the app and study materials and videos (i.e., are blind, deaf); and j) currently participating in a psychosocial intervention trial or individual/group psychotherapy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: HT Helper app use plus patient navigation support · Other: Usual Care
Behavioral: Patient Navigation support alone · Other: Usual Care
Control group
Other: Usual Care
HT Helper app plus patient navigation support to promote hormone therapy adherence among breast cancer patients experiencing NMDoH barriers
Patient navigation support to address NMDoH barriers impacting hormone therapy adherence
Usual care provided to patients who are prescribed hormone therapy and attend the Breast Clinic at the Mays Cancer Center
Adherence to hormone therapy
Adherence to HT, defined as the percentage of doses taken as prescribed, with optimal adherence considered at ≥80%.
Time frame: From enrollment to end of the intervention at 18 months
Self-efficacy for Appropriate Medication Use Scale (SEAMS)
Self-efficacy for medication adherence will be measured using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a validated 13-item instrument with three-point Likert scale response options ranging from 1=not confident to 3=very confident.Total scores range from 13-39 with a higher score indicating better confidence in self-efficacy.
Time frame: From enrollment to the end of the intervention at 18 months
Social support
Social support will be measured by the Multidimensional Scale of Perceived Social Support. This is a validated instrument with 12 questions rating three sources of support (family, friends, and significant others). Response options include a 7-point Likert scale ranging from 1=very strongly disagree to 7=very strongly agree. Total scores range from 12-84 with a higher score indicating stronger perceived social support.
Time frame: From enrollment to the end of the intervention at 18 months
Hormone therapy medication side effects
HT side effects will be assessed with the validated BCPT Symptoms Scale, which includes 25 of the most common cancer treatment symptoms, with response options using a 5-item Likert scale ranging from 0=not at all to 4=extremely. Total scores range from 0-72 with a higher score indicating more side effects experienced
Time frame: From enrollment to the end of the intervention at 18 months
Quality of life questionnaire
Quality of life (QoL) will be measured by the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire. This questionnaire is well validated and has been used in multiple studies around the world.The FACT-G Version 4 is a 27-item, 5-point Likert scale questionnaire (0=Not at all to 4=Very much) measuring cancer patient quality of life, scoring between 0 and 108, where higher scores indicate better QoL. It is scored by reversing negatively phrased items, summing 4 subscales (Physical Well Being, Social/Family Well Being, Emotional Well Being, Functional Well Being), and requires \>80% completion.
Time frame: From enrollment to the end of the intervention at 18 months
Depression
Depression will be assessed by the Patient Health Questionnaire (PHQ-8), an 8-item self-administered screening tool that has been validated in large clinical and population studies. Items are scored from 0=Not at all to 3=Nearly every day. Total scores range from 0-24 with a higher score indicating a higher degree of depression
Time frame: From enrollment to the end of the intervention at 18 months
Anxiety
Anxiety will be assessed by the G 7-item scale (GAD-7), a validated tool used in clinical practice and research studies to assess the severity of anxiety. Each item is scored from 0=Not at all sure to 3=Nearly every day. Total scores range from 0-21 with a higher score indicating more anxiety.
Time frame: From enrollment to the end of the intervention at 18 months
Started Sep 2025 (actual). Primary completion is estimated for Apr 2028, 31 months after the start.
Of 180 non-industry interventional studies with no phase under Treatment Adherence and Compliance, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 31 months is above that.
Counting every sponsor, half of 185 studies reached it within 17 months; a quarter within 9 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Treatment Adherence and Compliance →
The University of Texas Health Science Center at San Antonio →